ArticleJournal of virology2021
Evaluating a New Class of AKT/mTOR Activators for HIV Latency Reversing Activity
Open access · greenAbstract read
In one paragraph
Article in Journal of virology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
2.4field-weighted citation impact, top 11% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 24 citations in OpenAlex.
- Article
- XQ2, a Novel Derivative of Resveratrol, Reactivates Latent HIV‑1 via the Activation of Positive Transcription Elongation Factor B.ACS omega · 2026Article
- Host-directed approaches in the pursuit of a cure for HIV.Antiviral research · 2025Review
- Xenon gas as a potential treatment for opioid use disorder, alcohol use disorder, and related disorders.Medical gas research · 2025Review
- Discovery of Dual Targeting GSK-3β/HIV-1 Reverse Transcriptase Inhibitors as Neuroprotective Antiviral Agents.ACS chemical neuroscience · 2025Article
- High concentrations of Maraviroc do not alter immunological and metabolic parameters of CD4 T cells.Scientific reports · 2024Article
- Quantitative and Qualitative Distinctions between HIV-1 and SIV Reservoirs: Implications for HIV-1 Cure-Related Studies.Viruses · 2024Review
- Scopoletin Reactivates Latent HIV-1 by Inducing NF-κB Expression without Global T Cell Activation.International journal of molecular sciences · 2023Article
- Ponatinib Represses Latent HIV-1 by Inhibiting AKT-mTOR.Antimicrobial agents and chemotherapy · 2023Article
- Current strategies to induce selective killing of HIV-1-infected cells.Journal of leukocyte biology · 2022Review
- Tideglusib promotes wound healing in aged skin by activating PI3K/Akt pathway.Stem cell research & therapy · 2022Article
- Transforming dysfunctional CD8+ T cells into natural controller-like CD8+ T cells: can TCF-1 be the magic wand?The Journal of clinical investigation · 2022Article
- Combined noncanonical NF-κB agonism and targeted BET bromodomain inhibition reverse HIV latency ex vivo.The Journal of clinical investigation · 2022Article
- The ingenol-based protein kinase C agonist GSK445A is a potent inducer of HIV and SIV RNA transcription.PLoS pathogens · 2022Article
- HIV-1 replication and latency are balanced by mTOR-driven cell metabolism.Frontiers in cellular and infection microbiology · 2022Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
32 authors at 7 institutions in 3 countries.
Andrea GramaticaGladstone Institute of Virology, Gladstone Institutes, San Francisco, California, USA.
Roland SchwarzerGladstone Institute of Virology, Gladstone Institutes, San Francisco, California, USA.
William BrantleyVaccine and Gene Therapy Institute and Oregon National Primate Research Center, Oregon Health & Science University, Beaverton, Oregon, USA.
Benjamin Varco-MerthVaccine and Gene Therapy Institute and Oregon National Primate Research Center, Oregon Health & Science University, Beaverton, Oregon, USA.
Hannah S SperberVitalant Research Institute, San Francisco, California, USA.
Philip A HullGladstone Institute of Virology, Gladstone Institutes, San Francisco, California, USA.
Mauricio MontanoGladstone Institute of Virology, Gladstone Institutes, San Francisco, California, USA.
Stephen A MiguelesNational Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA.
Danielle RosenthalNational Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA.
Louise E HoganDepartment of Medicine, University of California, San Francisco, San Francisco, California, USA.
Jeffrey R JohnsonGladstone Institute of Virology, Gladstone Institutes, San Francisco, California, USA.
Thomas A PackardGladstone Institute of Virology, Gladstone Institutes, San Francisco, California, USA.
Zachary W GrimmettGladstone Institute of Virology, Gladstone Institutes, San Francisco, California, USA.
Eytan HerzigGladstone Institute of Virology, Gladstone Institutes, San Francisco, California, USA.
Emilie BesnardGladstone Institute of Virology, Gladstone Institutes, San Francisco, California, USA.
Michael NekorchukVaccine and Gene Therapy Institute and Oregon National Primate Research Center, Oregon Health & Science University, Beaverton, Oregon, USA.
Feng HsiaoGladstone Institute of Virology, Gladstone Institutes, San Francisco, California, USA.
Steven G DeeksDepartment of Medicine, University of California, San Francisco, San Francisco, California, USA.
Michael SnapeAMO Pharma Ltd., London, United Kingdom.
Bernard KiernanAMO Pharma Ltd., London, United Kingdom.
Nadia R RoanGladstone Institute of Virology, Gladstone Institutes, San Francisco, California, USA.
Jeffrey D LifsonAIDS and Cancer Virus Program, Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, Frederick, Maryland, USA.
Jacob D EstesVaccine and Gene Therapy Institute and Oregon National Primate Research Center, Oregon Health & Science University, Beaverton, Oregon, USA.
Louis J PickerVaccine and Gene Therapy Institute and Oregon National Primate Research Center, Oregon Health & Science University, Beaverton, Oregon, USA.
Eric VerdinGladstone Institute of Virology, Gladstone Institutes, San Francisco, California, USA.
Nevan J KroganGladstone Institute of Virology, Gladstone Institutes, San Francisco, California, USA.
Timothy J HenrichDepartment of Medicine, University of California, San Francisco, San Francisco, California, USA.
Mark ConnorsNational Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA.
Melanie OttGladstone Institute of Virology, Gladstone Institutes, San Francisco, California, USA.
Satish K PillaiDepartment of Laboratory Medicine, University of California, San Francisco, San Francisco, California, USA.
Afam A OkoyeVaccine and Gene Therapy Institute and Oregon National Primate Research Center, Oregon Health & Science University, Beaverton, Oregon, USA warner.greene@gladstone.ucsf.edu okoyea@ohsu.edu.
Warner C GreeneGladstone Institute of Virology, Gladstone Institutes, San Francisco, California, USA warner.greene@gladstone.ucsf.edu okoyea@ohsu.edu.ORCID https://orcid.org/0000-0001-9896-8615
Gladstone Institutes · USOregon National Primate Research Center · USUniversity of California, San Francisco · USNational Institutes of Health · USAMO Pharma (United Kingdom) · GBLeidos (United States) · USPacific Research Institute · US
Funding
Upgrade of confocal microscopy at the Oregon National Primate Research CenterP51OD011092 · OD · OREGON HEALTH & SCIENCE UNIVERSITY · PI Bonnie J. Nagel · 2012 to 2026
$203.9MVirology CoreP30AI027763 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI STEVEN Grant DEEKS · 1988 to 2026
$93.6MMechanisms Of Immune Mediated Restriction Of HIV Replication In LTNPZIAAI000855 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI CONNORS, MARK · 2009 to 2025
$20.0MProject 3: Identifying plasma biomarkers predicting time to HIV rebound after treatment interruptionP01AI131374 · NIAID · J. DAVID GLADSTONE INSTITUTES · PI ROAN, NADIA R · 2017 to 2021
$8.5MRole of Factor Acetylation in the Regulation of HIV TranscriptionR37AI083139 · NIAID · J. DAVID GLADSTONE INSTITUTES · PI Melanie Maria Ott · 2019 to 2026
$5.5MPhenotypic and mechanistic analysis of the in vivo HIV latent reservoir by single-cell technologiesR01AI147777 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI ROAN, NADIA R · 2019 to 2022
$3.8MElucidating the mechanism of progesterone-induced permissivity in the upperfemale reproductive tractR01AI127219 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI ROAN, NADIA R · 2016 to 2020
$2.1MEffects of Human Galectin-9 on the CNS HIV ReservoirR01MH112457 · NIMH · VITALANT · PI NDHLOVU, LISHOMWA C, PILLAI, SATISH KUMAR · 2016 to 2020
$2.0MEffects of Cell-Intrinsic Immunity on Establishment and Reversal of HIV LatencyR01GM117901 · NIGMS · VITALANT · PI PILLAI, SATISH KUMAR · 2015 to 2018
$1.5MEffects of Cell-Intrinsic Immunity on Establishment and Reversal of HIV LatencyR01AI150449 · NIAID · VITALANT · PI PILLAI, SATISH KUMAR · 2019 to 2019
$305kSlide Scanner for the ONPRC Imaging and Morphology CoreS10OD025002 · OD · OREGON HEALTH & SCIENCE UNIVERSITY · PI SRINIVASAN, SATHYA · 2018 to 2018
$146kCCR NIH HHS HHSN261200800001CNCI NIH HHS HHSN261200800001ENIAID NIH HHS P01 AI131374NIAID NIH HHS P30 AI027763NIAID NIH HHS R01 AI127219NIAID NIH HHS R01 AI147777NIAID NIH HHS R01 AI150449NIAID NIH HHS R37 AI083139NIGMS NIH HHS R01 GM117901NIH HHS P51 OD011092NIH HHS S10 OD025002NIMH NIH HHS R01 MH112457
Abstract
An ability to activate latent HIV-1 expression could benefit many HIV cure strategies, but the first generation of latency reversing agents (LRAs) has proven disappointing. We evaluated AKT/mTOR activators as a potential new class of LRAs. Two glycogen synthase kinase-3 inhibitors (GSK-3i's), SB-216763 and tideglusib (the latter already in phase II clinical trials) that activate AKT/mTOR signaling were tested. These GSK-3i's reactivated latent HIV-1 present in blood samples from aviremic individuals on antiretroviral therapy (ART) in the absence of T cell activation, release of inflammatory cytokines, cell toxicity, or impaired effector function of cytotoxic T lymphocytes or NK cells. However, when administered
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.